Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials

BACKGROUND: In addition to the increased risk for cardiovascular (CV) disease and CV events associated with migraine, patients with migraine can also present with a number of CV risk factors (CVRFs). Existing treatment options can be limited due to contraindications, increased burden associated with...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Headache Pain
Hlavní autoři: Shapiro, Robert E., Hochstetler, Helen M., Dennehy, Ellen B., Khanna, Rashna, Doty, Erin Gautier, Berg, Paul H., Starling, Amaal J.
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Milan 2019
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6734241/
https://ncbi.nlm.nih.gov/pubmed/31464581
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s10194-019-1044-6
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky